OraSure Technologies Acquires CoreBiome and Novosanis

OraSure Technologies Acquires UrSure

May 29, 2020

Medical Devices

OraSure Technologies, Inc. has agreed to acquire UrSure, Inc., a Boston-based developer of tests that measure adherence to HIV medications including PrEP, for $3 million upfront plus up to $28 million in contingent consideration. The acquisition expands OraSure's point-of-care and infectious disease diagnostic offerings and strengthens its position in the HIV market by adding adherence-monitoring products and related laboratory capabilities.

Canopy Biosciences Acquires Core Diagnostics

December 4, 2019

Biotechnology

Canopy Biosciences, a St. Louis-based multi-omic services company backed by Ampersand Capital Partners, has acquired Core Diagnostics, a California CLIA-certified biomarker analysis laboratory. The acquisition gives Canopy CLIA-certified laboratory capabilities to offer its multi-omic immune profiling services to clinical as well as preclinical and translational customers.

Premier Biotech (ACP) Acquires OraSure Toxicology Line and Green Earth Biomedical's Mexican Subsidiary (GEM)

April 10, 2025

Medical Devices

Premier Biotech, a portfolio company of Align Capital Partners, acquired certain assets comprising OraSure Technologies' substance abuse testing business line and the Mexican subsidiary of Green Earth Biomedical LLC (GEM). The transactions expand Premier's oral-fluid toxicology product portfolio and accelerate its international distribution footprint in Mexico and Latin America.

Bruker Corporation Acquires biocrates life sciences ag

June 3, 2025

Biotechnology

Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.

OmniActive Health Technologies Acquires ENovate Biolife

November 4, 2024

Food & Beverage

OmniActive Health Technologies has acquired ENovate Biolife to expand its portfolio of clinically validated botanical and specialty active ingredients for dietary supplements, functional foods and sports nutrition. The acquisition strengthens OmniActive's R&D, clinical and commercial capabilities and aims to accelerate global distribution of ENovate's ingredients such as Muvz, RedNite and Oxyjun.